サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：静注液の市場規模、市場シェア、アプリケーション分析、地域展望、成長動向、主要企業、競合戦略、予測、2023年～2031年
市場調査レポート
商品コード
1283947

静注液の市場規模、市場シェア、アプリケーション分析、地域展望、成長動向、主要企業、競合戦略、予測、2023年～2031年

Intravenous Solutions Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2023 To 2031
出版日: | 発行: Acute Market Reports | ページ情報: 英文 115 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
静注液の市場規模、市場シェア、アプリケーション分析、地域展望、成長動向、主要企業、競合戦略、予測、2023年～2031年
出版日: 2023年05月12日
発行: Acute Market Reports
ページ情報: 英文 115 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

静注液市場は、2031年までに8.0%の成長が見込まれます。静注液は、患者が必要な栄養を摂取できるようにサポートする栄養素の組み合わせを提供します。静注液の世界の需要は堅調に推移しており、アジア太平洋地域で高い成長を示しています。静脈内投与製品は、品質と入手可能性を保証するために高度に規制されています。成熟した市場でありながら、継続的な進化を遂げているため、安定した成長を遂げています。

静注液の世界のメーカーやベンダーは、製品の性質や販売・流通方法を常に改良しています。いくつかの大手企業は、直販部隊や独立系ディストリビューター、小売業者、卸売業者を採用しています。また、メーカーが収益性を維持するために、代替的な供給方法を採用しています。新興国市場では、メーカーに代わって製品を保管・配送するサードパーティが大きな足場を築いています。この種のベンダーは、常に十分な在庫を確保しているため、迅速な顧客サービスを提供することができます。この市場におけるその他の販売方法としては、顧客や販売サービス担当者を通じての販売、カタログの配布と商品化、電子購入機能および関連する利点、電子メールキャンペーン、業界紙や見本市などによる宣伝などがあります。

市場参入企業

Amanta Healthcare Ltd.、Axa Parenterals Ltd.、B. Braun Melsungen AG、Baxter International Inc.、Becton、Dickinson and Company、Eurolife Healthcare Pvt Ltd.,Fresenius Kabi AG、Grifols S.A、Henry Schein Inc.、ICU Medical、Inc.、JW Life Science、Otsuka Pharmaceutical Co.、Ltd.、Pfizer、Inc.、Salius Pharma Private Limited、Sichuan Kelun Pharmaceutical Co. Ltd、Soxa Formulations & Research (Pvt.) Ltd.、Vifor Pharma Management Ltd.など

目次

第1章 序文

  • レポート内容
    • 報告書の目的
    • 対象読者
    • 主な提供商品
  • 市場セグメンテーション
  • 調査手法
    • フェーズⅠ-二次調査
    • フェーズⅡ-一次調査
    • フェーズⅢ-有識者別レビュー
    • 前提条件
    • 採用したアプローチ

第2章 エグゼクティブサマリー

第3章 静注液市場：競合分析

  • 主要ベンダーの市場での位置付け
  • ベンダーが採用する戦略
  • 主要な産業戦略
  • ティア分析：2022 vs 2031

第4章 静注液市場：マクロ分析と市場力学

  • イントロダクション
  • 世界の静注液市場価値 2021-2031
  • 市場力学
    • 市場促進要因
    • 市場抑制要因
    • 主な課題
    • 主な機会
  • 促進要因と抑制要因の影響分析
  • シーソー分析

第5章 静注液のタイプ別市場 2021-2031

  • 市場概要
  • 成長・収益分析：2022 vs 2031
  • 市場セグメンテーション
    • 部分非経口栄養法
      • 年齢層
    • 完全非経口栄養学
      • 年齢層

第6章 静注液の構成別市場 2021-2031

  • 市場概要
  • 成長・収益分析：2022 vs 2031
  • 市場セグメンテーション
    • 炭水化物
    • ビタミンとミネラル
    • 単回投与アミノ酸
    • 非経口脂質エマルジョン
    • その他

第7章 静注液のエンドユーザー別市場 2021-2031

  • 市場概要
  • 成長・収益分析：2022 vs 2031
  • 市場セグメンテーション
    • 病院と診療所
    • 外来手術センター
    • 在宅ケアの設定

第8章 北米静注液市場 2021-2031

  • 市場概要
  • 静注液のタイプ別市場 2021-2031
  • 静注液の構成別市場 2021-2031
  • 静注液のエンドユーザー別の市場 2021-2031
  • 静注液の地域別市場 2021-2031
    • 北米
      • 米国
      • カナダ
      • その他北米地域

第9章 英国および欧州連合静注液市場 2021-2031

  • 市場概要
  • 静注液のタイプ別市場 2021-2031
  • 静注液の構成別市場 2021-2031
  • 静注液のエンドユーザー別の市場 2021-2031
  • 静注液の地域別市場 2021-2031
    • 英国と欧州連合
      • 英国
      • ドイツ
      • スペイン
      • イタリア
      • フランス
      • その他欧州地域

第10章 アジア太平洋静注液市場 2021-2031

  • 市場概要
  • 静注液のタイプ別市場 2021-2031
  • 静注液の構成別市場 2021-2031
  • 静注液のエンドユーザー別の市場 2021-2031
  • 静注液の地域別市場 2021-2031
    • アジア太平洋
      • 中国
      • 日本
      • インド
      • オーストラリア
      • 韓国
      • その他アジア太平洋地域

第11章 ラテンアメリカ静注液市場 2021-2031

  • 市場概要
  • 静注液のタイプ別市場 2021-2031
  • 静注液の構成別市場 2021-2031
  • 静注液のエンドユーザー別の市場 2021-2031
  • 静注液の地域別市場 2021-2031
    • ラテンアメリカ
      • ブラジル
      • メキシコ
      • その他ラテンアメリカ地域

第12章 中東およびアフリカ静注液市場 2021-2031

  • 市場概要
  • 静注液のタイプ別市場 2021-2031
  • 静注液の構成別市場 2021-2031
  • 静注液のエンドユーザー別の市場 2021-2031
  • 静注液の地域別市場 2021-2031
    • 中東・アフリカ
      • GCC
      • アフリカ
      • その他中東・アフリカ地域

第13章 企業プロファイル

  • Amanta Healthcare Ltd.
  • Axa Parenterals Ltd.
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Becton Dickinson and Company
  • Eurolife Healthcare Pvt Ltd.
  • Fresenius Kabi AG
  • Grifols S.A
  • Henry Schein Inc.
  • ICU Medical Inc.
  • JW Life Science
  • Otsuka Pharmaceutical Co. Ltd.
  • Pfizer Inc.
  • Salius Pharma Private Limited
  • Sichuan Kelun Pharmaceutical Co. Ltd
  • Soxa Formulations & Research（Pvt.）Ltd.
  • Vifor Pharma Management Ltd.
  • その他
図表

List of Tables

  • TABLE 1 Global Intravenous Solutions Market By Type, 2021-2031, USD (Million)
  • TABLE 2 Global Intravenous Solutions Market By Partial Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 3 Global Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 4 Global Intravenous Solutions Market By Total Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 5 Global Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 6 Global Intravenous Solutions Market By Composition, 2021-2031, USD (Million)
  • TABLE 7 Global Intravenous Solutions Market By End Users, 2021-2031, USD (Million)
  • TABLE 8 North America Intravenous Solutions Market By Type, 2021-2031, USD (Million)
  • TABLE 9 North America Intravenous Solutions Market By Partial Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 10 North America Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 11 North America Intravenous Solutions Market By Total Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 12 North America Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 13 North America Intravenous Solutions Market By Composition, 2021-2031, USD (Million)
  • TABLE 14 North America Intravenous Solutions Market By End Users, 2021-2031, USD (Million)
  • TABLE 15 U.S. Intravenous Solutions Market By Type, 2021-2031, USD (Million)
  • TABLE 16 U.S. Intravenous Solutions Market By Partial Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 17 U.S. Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 18 U.S. Intravenous Solutions Market By Total Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 19 U.S. Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 20 U.S. Intravenous Solutions Market By Composition, 2021-2031, USD (Million)
  • TABLE 21 U.S. Intravenous Solutions Market By End Users, 2021-2031, USD (Million)
  • TABLE 22 Canada Intravenous Solutions Market By Type, 2021-2031, USD (Million)
  • TABLE 23 Canada Intravenous Solutions Market By Partial Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 24 Canada Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 25 Canada Intravenous Solutions Market By Total Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 26 Canada Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 27 Canada Intravenous Solutions Market By Composition, 2021-2031, USD (Million)
  • TABLE 28 Canada Intravenous Solutions Market By End Users, 2021-2031, USD (Million)
  • TABLE 29 Rest of North America Intravenous Solutions Market By Type, 2021-2031, USD (Million)
  • TABLE 30 Rest of North America Intravenous Solutions Market By Partial Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 31 Rest of North America Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 32 Rest of North America Intravenous Solutions Market By Total Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 33 Rest of North America Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 34 Rest of North America Intravenous Solutions Market By Composition, 2021-2031, USD (Million)
  • TABLE 35 Rest of North America Intravenous Solutions Market By End Users, 2021-2031, USD (Million)
  • TABLE 36 UK and European Union Intravenous Solutions Market By Type, 2021-2031, USD (Million)
  • TABLE 37 UK and European Union Intravenous Solutions Market By Partial Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 38 UK and European Union Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 39 UK and European Union Intravenous Solutions Market By Total Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 40 UK and European Union Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 41 UK and European Union Intravenous Solutions Market By Composition, 2021-2031, USD (Million)
  • TABLE 42 UK and European Union Intravenous Solutions Market By End Users, 2021-2031, USD (Million)
  • TABLE 43 UK Intravenous Solutions Market By Type, 2021-2031, USD (Million)
  • TABLE 44 UK Intravenous Solutions Market By Partial Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 45 UK Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 46 UK Intravenous Solutions Market By Total Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 47 UK Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 48 UK Intravenous Solutions Market By Composition, 2021-2031, USD (Million)
  • TABLE 49 UK Intravenous Solutions Market By End Users, 2021-2031, USD (Million)
  • TABLE 50 Germany Intravenous Solutions Market By Type, 2021-2031, USD (Million)
  • TABLE 51 Germany Intravenous Solutions Market By Partial Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 52 Germany Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 53 Germany Intravenous Solutions Market By Total Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 54 Germany Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 55 Germany Intravenous Solutions Market By Composition, 2021-2031, USD (Million)
  • TABLE 56 Germany Intravenous Solutions Market By End Users, 2021-2031, USD (Million)
  • TABLE 57 Spain Intravenous Solutions Market By Type, 2021-2031, USD (Million)
  • TABLE 58 Spain Intravenous Solutions Market By Partial Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 59 Spain Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 60 Spain Intravenous Solutions Market By Total Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 61 Spain Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 62 Spain Intravenous Solutions Market By Composition, 2021-2031, USD (Million)
  • TABLE 63 Spain Intravenous Solutions Market By End Users, 2021-2031, USD (Million)
  • TABLE 64 Italy Intravenous Solutions Market By Type, 2021-2031, USD (Million)
  • TABLE 65 Italy Intravenous Solutions Market By Partial Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 66 Italy Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 67 Italy Intravenous Solutions Market By Total Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 68 Italy Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 69 Italy Intravenous Solutions Market By Composition, 2021-2031, USD (Million)
  • TABLE 70 Italy Intravenous Solutions Market By End Users, 2021-2031, USD (Million)
  • TABLE 71 France Intravenous Solutions Market By Type, 2021-2031, USD (Million)
  • TABLE 72 France Intravenous Solutions Market By Partial Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 73 France Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 74 France Intravenous Solutions Market By Total Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 75 France Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 76 France Intravenous Solutions Market By Composition, 2021-2031, USD (Million)
  • TABLE 77 France Intravenous Solutions Market By End Users, 2021-2031, USD (Million)
  • TABLE 78 Rest of Europe Intravenous Solutions Market By Type, 2021-2031, USD (Million)
  • TABLE 79 Rest of Europe Intravenous Solutions Market By Partial Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 80 Rest of Europe Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 81 Rest of Europe Intravenous Solutions Market By Total Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 82 Rest of Europe Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 83 Rest of Europe Intravenous Solutions Market By Composition, 2021-2031, USD (Million)
  • TABLE 84 Rest of Europe Intravenous Solutions Market By End Users, 2021-2031, USD (Million)
  • TABLE 85 Asia Intravenous Solutions Market By Type, 2021-2031, USD (Million)
  • TABLE 86 Asia Intravenous Solutions Market By Partial Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 87 Asia Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 88 Asia Intravenous Solutions Market By Total Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 89 Asia Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 90 Asia Intravenous Solutions Market By Composition, 2021-2031, USD (Million)
  • TABLE 91 Asia Intravenous Solutions Market By End Users, 2021-2031, USD (Million)
  • TABLE 92 China Intravenous Solutions Market By Type, 2021-2031, USD (Million)
  • TABLE 93 China Intravenous Solutions Market By Partial Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 94 China Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 95 China Intravenous Solutions Market By Total Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 96 China Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 97 China Intravenous Solutions Market By Composition, 2021-2031, USD (Million)
  • TABLE 98 China Intravenous Solutions Market By End Users, 2021-2031, USD (Million)
  • TABLE 99 Japan Intravenous Solutions Market By Type, 2021-2031, USD (Million)
  • TABLE 100 Japan Intravenous Solutions Market By Partial Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 101 Japan Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 102 Japan Intravenous Solutions Market By Total Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 103 Japan Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 104 Japan Intravenous Solutions Market By Composition, 2021-2031, USD (Million)
  • TABLE 105 Japan Intravenous Solutions Market By End Users, 2021-2031, USD (Million)
  • TABLE 106 India Intravenous Solutions Market By Type, 2021-2031, USD (Million)
  • TABLE 107 India Intravenous Solutions Market By Partial Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 108 India Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 109 India Intravenous Solutions Market By Total Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 110 India Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 111 India Intravenous Solutions Market By Composition, 2021-2031, USD (Million)
  • TABLE 112 India Intravenous Solutions Market By End Users, 2021-2031, USD (Million)
  • TABLE 113 Australia Intravenous Solutions Market By Type, 2021-2031, USD (Million)
  • TABLE 114 Australia Intravenous Solutions Market By Partial Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 115 Australia Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 116 Australia Intravenous Solutions Market By Total Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 117 Australia Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 118 Australia Intravenous Solutions Market By Composition, 2021-2031, USD (Million)
  • TABLE 119 Australia Intravenous Solutions Market By End Users, 2021-2031, USD (Million)
  • TABLE 120 South Korea Intravenous Solutions Market By Type, 2021-2031, USD (Million)
  • TABLE 121 South Korea Intravenous Solutions Market By Partial Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 122 South Korea Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 123 South Korea Intravenous Solutions Market By Total Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 124 South Korea Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 125 South Korea Intravenous Solutions Market By Composition, 2021-2031, USD (Million)
  • TABLE 126 South Korea Intravenous Solutions Market By End Users, 2021-2031, USD (Million)
  • TABLE 127 Latin America Intravenous Solutions Market By Type, 2021-2031, USD (Million)
  • TABLE 128 Latin America Intravenous Solutions Market By Partial Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 129 Latin America Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 130 Latin America Intravenous Solutions Market By Total Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 131 Latin America Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 132 Latin America Intravenous Solutions Market By Composition, 2021-2031, USD (Million)
  • TABLE 133 Latin America Intravenous Solutions Market By End Users, 2021-2031, USD (Million)
  • TABLE 134 Brazil Intravenous Solutions Market By Type, 2021-2031, USD (Million)
  • TABLE 135 Brazil Intravenous Solutions Market By Partial Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 136 Brazil Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 137 Brazil Intravenous Solutions Market By Total Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 138 Brazil Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 139 Brazil Intravenous Solutions Market By Composition, 2021-2031, USD (Million)
  • TABLE 140 Brazil Intravenous Solutions Market By End Users, 2021-2031, USD (Million)
  • TABLE 141 Mexico Intravenous Solutions Market By Type, 2021-2031, USD (Million)
  • TABLE 142 Mexico Intravenous Solutions Market By Partial Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 143 Mexico Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 144 Mexico Intravenous Solutions Market By Total Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 145 Mexico Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 146 Mexico Intravenous Solutions Market By Composition, 2021-2031, USD (Million)
  • TABLE 147 Mexico Intravenous Solutions Market By End Users, 2021-2031, USD (Million)
  • TABLE 148 Rest of Latin America Intravenous Solutions Market By Type, 2021-2031, USD (Million)
  • TABLE 149 Rest of Latin America Intravenous Solutions Market By Partial Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 150 Rest of Latin America Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 151 Rest of Latin America Intravenous Solutions Market By Total Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 152 Rest of Latin America Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 153 Rest of Latin America Intravenous Solutions Market By Composition, 2021-2031, USD (Million)
  • TABLE 154 Rest of Latin America Intravenous Solutions Market By End Users, 2021-2031, USD (Million)
  • TABLE 155 Middle East and Africa Intravenous Solutions Market By Type, 2021-2031, USD (Million)
  • TABLE 156 Middle East and Africa Intravenous Solutions Market By Partial Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 157 Middle East and Africa Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 158 Middle East and Africa Intravenous Solutions Market By Total Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 159 Middle East and Africa Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 160 Middle East and Africa Intravenous Solutions Market By Composition, 2021-2031, USD (Million)
  • TABLE 161 Middle East and Africa Intravenous Solutions Market By End Users, 2021-2031, USD (Million)
  • TABLE 162 GCC Intravenous Solutions Market By Type, 2021-2031, USD (Million)
  • TABLE 163 GCC Intravenous Solutions Market By Partial Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 164 GCC Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 165 GCC Intravenous Solutions Market By Total Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 166 GCC Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 167 GCC Intravenous Solutions Market By Composition, 2021-2031, USD (Million)
  • TABLE 168 GCC Intravenous Solutions Market By End Users, 2021-2031, USD (Million)
  • TABLE 169 Africa Intravenous Solutions Market By Type, 2021-2031, USD (Million)
  • TABLE 170 Africa Intravenous Solutions Market By Partial Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 171 Africa Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 172 Africa Intravenous Solutions Market By Total Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 173 Africa Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 174 Africa Intravenous Solutions Market By Composition, 2021-2031, USD (Million)
  • TABLE 175 Africa Intravenous Solutions Market By End Users, 2021-2031, USD (Million)
  • TABLE 176 Rest of Middle East and Africa Intravenous Solutions Market By Type, 2021-2031, USD (Million)
  • TABLE 177 Rest of Middle East and Africa Intravenous Solutions Market By Partial Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 178 Rest of Middle East and Africa Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 179 Rest of Middle East and Africa Intravenous Solutions Market By Total Parenteral Nutrition, 2021-2031, USD (Million)
  • TABLE 180 Rest of Middle East and Africa Intravenous Solutions Market By Age Group, 2021-2031, USD (Million)
  • TABLE 181 Rest of Middle East and Africa Intravenous Solutions Market By Composition, 2021-2031, USD (Million)
  • TABLE 182 Rest of Middle East and Africa Intravenous Solutions Market By End Users, 2021-2031, USD (Million)

List of Figures

  • FIG. 1 Global Intravenous Solutions Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Intravenous Solutions Market: Quality Assurance
  • FIG. 5 Global Intravenous Solutions Market, By Type, 2022
  • FIG. 6 Global Intravenous Solutions Market, By Composition, 2022
  • FIG. 7 Global Intravenous Solutions Market, By End Users, 2022
  • FIG. 8 Global Intravenous Solutions Market, By Geography, 2022
  • FIG. 9 Market Geographical Opportunity Matrix - Global Intravenous Solutions Market, 2022
  • FIG. 10 Market Positioning of Key Intravenous Solutions Market Players, 2022
  • FIG. 11 Global Intravenous Solutions Market - Tier Analysis - Percentage of Revenues by Tier Level, 2022 Versus 2031
  • FIG. 12 Global Intravenous Solutions Market, By Type, 2022 Vs 2031, %
  • FIG. 13 Global Intravenous Solutions Market, By Composition, 2022 Vs 2031, %
  • FIG. 14 Global Intravenous Solutions Market, By End Users, 2022 Vs 2031, %
  • FIG. 15 U.S. Intravenous Solutions Market (US$ Million), 2021 - 2031
  • FIG. 16 Canada Intravenous Solutions Market (US$ Million), 2021 - 2031
  • FIG. 17 Rest of North America Intravenous Solutions Market (US$ Million), 2021 - 2031
  • FIG. 18 UK Intravenous Solutions Market (US$ Million), 2021 - 2031
  • FIG. 19 Germany Intravenous Solutions Market (US$ Million), 2021 - 2031
  • FIG. 20 Spain Intravenous Solutions Market (US$ Million), 2021 - 2031
  • FIG. 21 Italy Intravenous Solutions Market (US$ Million), 2021 - 2031
  • FIG. 22 France Intravenous Solutions Market (US$ Million), 2021 - 2031
  • FIG. 23 Rest of Europe Intravenous Solutions Market (US$ Million), 2021 - 2031
  • FIG. 24 China Intravenous Solutions Market (US$ Million), 2021 - 2031
  • FIG. 25 Japan Intravenous Solutions Market (US$ Million), 2021 - 2031
  • FIG. 26 India Intravenous Solutions Market (US$ Million), 2021 - 2031
  • FIG. 27 Australia Intravenous Solutions Market (US$ Million), 2021 - 2031
  • FIG. 28 South Korea Intravenous Solutions Market (US$ Million), 2021 - 2031
  • FIG. 29 Rest of Asia Intravenous Solutions Market (US$ Million), 2021 - 2031
  • FIG. 30 Brazil Intravenous Solutions Market (US$ Million), 2021 - 2031
  • FIG. 31 Mexico Intravenous Solutions Market (US$ Million), 2021 - 2031
  • FIG. 32 Rest of Latin America Intravenous Solutions Market (US$ Million), 2021 - 2031
  • FIG. 33 GCC Intravenous Solutions Market (US$ Million), 2021 - 2031
  • FIG. 34 Africa Intravenous Solutions Market (US$ Million), 2021 - 2031
  • FIG. 35 Rest of Middle East and Africa Intravenous Solutions Market (US$ Million), 2021 - 2031
目次
Product Code: 136853-05-23

Intravenous Solutions Market is Expected to Grow at 8.0% by 2031. Intravenous solutions present a combination of nutrients that support patients to get essential nutrition. The demand for intravenous solutions on the global front is undergoing steady growth and its market presents a higher growth in the Asia-Pacific region. Intravenous products are highly regulated for quality and availability assurance. Though matured, this market has been undergoing continuous evolution, thus experiencing steady growth.

The intravenous solutions manufacturers and vendors worldwide are perpetually improving the nature of products, and sales and distribution methods respectively. Several large players have employed direct sales force and independent distributors, retail and wholesalers. Alternate modes of supply are also employed by the manufacturers to retain profitability. Third parties that store and deliver products for the manufacturer have a significant foothold in developed markets. These type of vendors are found to better cater swift customer service as they always stock adequate inventories. Other sales practices in this market include sales through customer and sales service representatives, catalogue circulation and merchandising, electronic purchase facility and allied benefits, e-mail campaign, publicity through trade publications and trade fairs and others.

Market Players

Amanta Healthcare Ltd., Axa Parenterals Ltd., B. Braun Melsungen AG, Baxter International Inc., Becton, Dickinson and Company, Eurolife Healthcare Pvt Ltd.,Fresenius Kabi AG, Grifols S.A, Henry Schein Inc., ICU Medical, Inc., JW Life Science, Otsuka Pharmaceutical Co., Ltd., Pfizer, Inc., Salius Pharma Private Limited, Sichuan Kelun Pharmaceutical Co. Ltd, Soxa Formulations & Research (Pvt.) Ltd., Vifor Pharma Management Ltd. And Other Notable Players.

Historical & Forecast Period

This study report represents analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2031.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Intravenous Solutions market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Intravenous Solutions market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Type

  • Partial Parenteral Nutrition
    • Age Group
    • Pediatric
    • Adult
  • Total Parenteral Nutrition
    • Age Group
    • Pediatric
    • Adult

Composition

  • Carbohydrates
  • Vitamins and Minerals
  • Single Dose Amino Acids
  • Parenteral Lipid Emulsion
  • Others

End Users

  • Hospitals and Clinics
  • Ambulatory Surgery Centers
  • Home care settings

Region Segment (2021-2031; US$ Million)

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • UK and European Union
    • UK
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa

Key questions answered in this report:

  • What are the key micro and macro environmental factors that are impacting the growth of Intravenous Solutions market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2031.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Intravenous Solutions market?
  • Which is the largest regional market for Intravenous Solutions market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Intravenous Solutions market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Intravenous Solutions market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Intravenous Solutions Market
  • 2.2. Global Intravenous Solutions Market, By Type, 2022 (US$ Million)
  • 2.3. Global Intravenous Solutions Market, By Composition, 2022 (US$ Million)
  • 2.4. Global Intravenous Solutions Market, By End Users, 2022 (US$ Million)
  • 2.5. Global Intravenous Solutions Market, By Geography, 2022 (US$ Million)
  • 2.6. Attractive Investment Proposition by Geography, 2022

3. Intravenous Solutions Market: Competitive Analysis

  • 3.1. Market Positioning of Key Intravenous Solutions Market Vendors
  • 3.2. Strategies Adopted by Intravenous Solutions Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2022 Versus 2031

4. Intravenous Solutions Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Intravenous Solutions Market Value, 2021 - 2031, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis

5. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 5.3. Market Segmentation
    • 5.3.1. Partial Parenteral Nutrition
      • 5.3.1.1. Age Group
        • 5.3.1.1.1. Pediatric
        • 5.3.1.1.2. Adult
    • 5.3.2. Total Parenteral Nutrition
      • 5.3.2.1. Age Group
        • 5.3.2.1.1. Pediatric
        • 5.3.2.1.2. Adult

6. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)

  • 6.1. Market Overview
  • 6.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 6.3. Market Segmentation
    • 6.3.1. Carbohydrates
    • 6.3.2. Vitamins and Minerals
    • 6.3.3. Single Dose Amino Acids
    • 6.3.4. Parenteral Lipid Emulsion
    • 6.3.5. Others

7. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)

  • 7.1. Market Overview
  • 7.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 7.3. Market Segmentation
    • 7.3.1. Hospitals and Clinics
    • 7.3.2. Ambulatory Surgery Centers
    • 7.3.3. Home care settings

8. North America Intravenous Solutions Market, 2021-2031, USD (Million)

  • 8.1. Market Overview
  • 8.2. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
  • 8.3. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
  • 8.4. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
  • 8.5.Intravenous Solutions Market: By Region, 2021-2031, USD (Million)
    • 8.5.1.North America
      • 8.5.1.1. U.S.
        • 8.5.1.1.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 8.5.1.1.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 8.5.1.1.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
      • 8.5.1.2. Canada
        • 8.5.1.2.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 8.5.1.2.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 8.5.1.2.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
      • 8.5.1.3. Rest of North America
        • 8.5.1.3.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 8.5.1.3.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 8.5.1.3.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)

9. UK and European Union Intravenous Solutions Market, 2021-2031, USD (Million)

  • 9.1. Market Overview
  • 9.2. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
  • 9.3. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
  • 9.4. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
  • 9.5.Intravenous Solutions Market: By Region, 2021-2031, USD (Million)
    • 9.5.1.UK and European Union
      • 9.5.1.1. UK
        • 9.5.1.1.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 9.5.1.1.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 9.5.1.1.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
      • 9.5.1.2. Germany
        • 9.5.1.2.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 9.5.1.2.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 9.5.1.2.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
      • 9.5.1.3. Spain
        • 9.5.1.3.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 9.5.1.3.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 9.5.1.3.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
      • 9.5.1.4. Italy
        • 9.5.1.4.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 9.5.1.4.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 9.5.1.4.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
      • 9.5.1.5. France
        • 9.5.1.5.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 9.5.1.5.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 9.5.1.5.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
      • 9.5.1.6. Rest of Europe
        • 9.5.1.6.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 9.5.1.6.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 9.5.1.6.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)

10. Asia Pacific Intravenous Solutions Market, 2021-2031, USD (Million)

  • 10.1. Market Overview
  • 10.2. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
  • 10.3. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
  • 10.4. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
  • 10.5.Intravenous Solutions Market: By Region, 2021-2031, USD (Million)
    • 10.5.1.Asia Pacific
      • 10.5.1.1. China
        • 10.5.1.1.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 10.5.1.1.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 10.5.1.1.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
      • 10.5.1.2. Japan
        • 10.5.1.2.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 10.5.1.2.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 10.5.1.2.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
      • 10.5.1.3. India
        • 10.5.1.3.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 10.5.1.3.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 10.5.1.3.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
      • 10.5.1.4. Australia
        • 10.5.1.4.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 10.5.1.4.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 10.5.1.4.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
      • 10.5.1.5. South Korea
        • 10.5.1.5.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 10.5.1.5.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 10.5.1.5.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
      • 10.5.1.6. Rest of Asia Pacific
        • 10.5.1.6.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 10.5.1.6.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 10.5.1.6.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)

11. Latin America Intravenous Solutions Market, 2021-2031, USD (Million)

  • 11.1. Market Overview
  • 11.2. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
  • 11.3. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
  • 11.4. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
  • 11.5.Intravenous Solutions Market: By Region, 2021-2031, USD (Million)
    • 11.5.1.Latin America
      • 11.5.1.1. Brazil
        • 11.5.1.1.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 11.5.1.1.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 11.5.1.1.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
      • 11.5.1.2. Mexico
        • 11.5.1.2.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 11.5.1.2.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 11.5.1.2.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
      • 11.5.1.3. Rest of Latin America
        • 11.5.1.3.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 11.5.1.3.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 11.5.1.3.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)

12. Middle East and Africa Intravenous Solutions Market, 2021-2031, USD (Million)

  • 12.1. Market Overview
  • 12.2. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
  • 12.3. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
  • 12.4. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
  • 12.5.Intravenous Solutions Market: By Region, 2021-2031, USD (Million)
    • 12.5.1.Middle East and Africa
      • 12.5.1.1. GCC
        • 12.5.1.1.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 12.5.1.1.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 12.5.1.1.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
      • 12.5.1.2. Africa
        • 12.5.1.2.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 12.5.1.2.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 12.5.1.2.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)
      • 12.5.1.3. Rest of Middle East and Africa
        • 12.5.1.3.1. Intravenous Solutions Market: By Type, 2021-2031, USD (Million)
        • 12.5.1.3.1. Intravenous Solutions Market: By Composition, 2021-2031, USD (Million)
        • 12.5.1.3.1. Intravenous Solutions Market: By End Users, 2021-2031, USD (Million)

13. Company Profile

  • 13.1. Amanta Healthcare Ltd.
    • 13.1.1. Company Overview
    • 13.1.2. Financial Performance
    • 13.1.3. Product Portfolio
    • 13.1.4. Strategic Initiatives
  • 13.2. Axa Parenterals Ltd.,
    • 13.2.1. Company Overview
    • 13.2.2. Financial Performance
    • 13.2.3. Product Portfolio
    • 13.2.4. Strategic Initiatives
  • 13.3. B. Braun Melsungen AG
    • 13.3.1. Company Overview
    • 13.3.2. Financial Performance
    • 13.3.3. Product Portfolio
    • 13.3.4. Strategic Initiatives
  • 13.4. Baxter International Inc.
    • 13.4.1. Company Overview
    • 13.4.2. Financial Performance
    • 13.4.3. Product Portfolio
    • 13.4.4. Strategic Initiatives
  • 13.5. Becton, Dickinson and Company
    • 13.5.1. Company Overview
    • 13.5.2. Financial Performance
    • 13.5.3. Product Portfolio
    • 13.5.4. Strategic Initiatives
  • 13.6. Eurolife Healthcare Pvt Ltd.
    • 13.6.1. Company Overview
    • 13.6.2. Financial Performance
    • 13.6.3. Product Portfolio
    • 13.6.4. Strategic Initiatives
  • 13.7. Fresenius Kabi AG
    • 13.7.1. Company Overview
    • 13.7.2. Financial Performance
    • 13.7.3. Product Portfolio
    • 13.7.4. Strategic Initiatives
  • 13.8. Grifols S.A
    • 13.8.1. Company Overview
    • 13.8.2. Financial Performance
    • 13.8.3. Product Portfolio
    • 13.8.4. Strategic Initiatives
  • 13.9. Henry Schein Inc.
    • 13.9.1. Company Overview
    • 13.9.2. Financial Performance
    • 13.9.3. Product Portfolio
    • 13.9.4. Strategic Initiatives
  • 13.10. ICU Medical, Inc.
    • 13.10.1. Company Overview
    • 13.10.2. Financial Performance
    • 13.10.3. Product Portfolio
    • 13.10.4. Strategic Initiatives
  • 13.11. JW Life Science
    • 13.11.1. Company Overview
    • 13.11.2. Financial Performance
    • 13.11.3. Product Portfolio
    • 13.11.4. Strategic Initiatives
  • 13.12. Otsuka Pharmaceutical Co., Ltd.
    • 13.12.1. Company Overview
    • 13.12.2. Financial Performance
    • 13.12.3. Product Portfolio
    • 13.12.4. Strategic Initiatives
  • 13.13. Pfizer, Inc.
    • 13.13.1. Company Overview
    • 13.13.2. Financial Performance
    • 13.13.3. Product Portfolio
    • 13.13.4. Strategic Initiatives
  • 13.14. Salius Pharma Private Limited
    • 13.14.1. Company Overview
    • 13.14.2. Financial Performance
    • 13.14.3. Product Portfolio
    • 13.14.4. Strategic Initiatives
  • 13.15. Sichuan Kelun Pharmaceutical Co. Ltd
    • 13.15.1. Company Overview
    • 13.15.2. Financial Performance
    • 13.15.3. Product Portfolio
    • 13.15.4. Strategic Initiatives
  • 13.16. Soxa Formulations & Research (Pvt.) Ltd.
    • 13.16.1. Company Overview
    • 13.16.2. Financial Performance
    • 13.16.3. Product Portfolio
    • 13.16.4. Strategic Initiatives
  • 13.17. Vifor Pharma Management Ltd.
    • 13.17.1. Company Overview
    • 13.17.2. Financial Performance
    • 13.17.3. Product Portfolio
    • 13.17.4. Strategic Initiatives
  • 13.18. Other Notable Players
    • 13.18.1. Company Overview
    • 13.18.2. Financial Performance
    • 13.18.3. Product Portfolio
    • 13.18.4. Strategic Initiatives